Nocturnal Enuresis Medication Global Market Report 2025

The nocturnal enuresis medication market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historical period can be attributed to the high global prevalence of nocturnal enuresis in children, growing awareness of adult nocturnal enuresis, an increasing pediatric population, higher diagnosis rates due to enhanced screening methods, and a rising incidence of comorbid conditions.

The nocturnal enuresis medication market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The expected growth in the forecast period is driven by factors such as an increase in stress-related bladder dysfunction in children, a rise in secondary enuresis cases following psychological trauma, government initiatives promoting child healthcare, the growth of telemedicine for remote diagnosis and treatment, and the rise of e-pharmacies enhancing drug accessibility. Key trends in the forecast period include advancements in drug formulations, the development of new delivery methods, the approval of new therapeutic agents, the growing popularity of combination therapies, and the acceleration of drug development timelines through AI and precision medicine.

The growing demand for personalized care is expected to drive the growth of the nocturnal enuresis medication market in the future. Personalized care involves tailoring treatments and healthcare strategies to an individual’s unique genetic profile, lifestyle, preferences, and specific health conditions, leading to more effective outcomes. This increasing demand is driven by advancements in medical technology that enable healthcare providers to customize treatments based on each patient’s genetic makeup and health conditions, resulting in more targeted and effective care. In the case of nocturnal enuresis medication, personalized care involves customizing treatment plans according to a patient's medical history and underlying causes, improving both the effectiveness and adherence to therapy. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. As a result, the demand for personalized care is fueling the growth of the nocturnal enuresis medication market.

Rising healthcare expenditure is expected to contribute to the growth of the nocturnal enuresis medication market in the coming years. Healthcare expenditure refers to the total spending on medical services, products, and public health by individuals, governments, and organizations over a specific period. The increase in healthcare spending is driven by factors such as the growing prevalence of chronic diseases, which require ongoing management and treatment, leading to higher costs for medications and specialized care. The rise in healthcare expenditure supports nocturnal enuresis medication by providing more investment in research, development, and access to advanced treatment options, thereby enhancing the availability and effectiveness of care for patients. For example, the Peterson-KFF Health System Tracker reported that US health spending was projected to reach $4.9 trillion in 2024, a 5% increase from $4.67 trillion in 2023. Therefore, rising healthcare expenditure is boosting the growth of the nocturnal enuresis medication market.

Companies operating in the nocturnal enuresis medication market are focusing on advanced solutions such as orally disintegrating tablets (ODT) to improve patient convenience. Orally disintegrating tablets are solid forms of medication that dissolve quickly in the mouth without the need for water, making them ideal for patients who have difficulty swallowing pills. For example, in March 2024, Adalvo Limited, a pharmaceutical company based in Malta, launched desmopressin orally disintegrating tablets in Europe. This formulation, designed specifically for treating primary nocturnal enuresis, provides a convenient option that disintegrates rapidly in the mouth. It is particularly beneficial for pediatric and elderly patients or those with difficulty swallowing. The launch reflects Adalvo’s commitment to offering differentiated pharmaceutical products and improving patient access to essential therapies through strategic partnerships.

Major players in the nocturnal enuresis medication market are Pfizer Inc., Merck & Co. Inc., Dr. Willmar Schwabe GmbH & Co. KG, Ferring Pharmaceuticals A/S, UroGen Pharma Ltd., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Nordic Pharma Group, Dr. Reckeweg & Co. GmbH, Chummie, Taiho Pharmaceutical Co. Ltd., AA Pharma Inc., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Aark Pharmaceuticals Ltd., Alturix Ltd., Wellesley Pharmaceuticals LLC, German Homoeo Care and Cure Pvt. Ltd., Laboratoires Ledoux Reflexe Inc., Global Continence Inc., Serenity Pharmaceuticals LLC, and Vantia Therapeutics Ltd.

North America was the largest region in the nocturnal enuresis medication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nocturnal enuresis medication report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nocturnal enuresis medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nocturnal enuresis medication refers to drugs designed to treat and alleviate involuntary urination during sleep, commonly known as bedwetting, which affects both children and, in some cases, adults. The primary aim is to improve bladder control, reduce the amount of urine produced overnight, or modify the body's natural sleep response to a full bladder.

The main classes of drugs used for nocturnal enuresis include desmopressin, imipramine, oxybutynin, combined pharmacotherapy, and antidepressants. Desmopressin is a synthetic hormone that helps reduce nighttime urine production and is often prescribed for treating nocturnal enuresis (bedwetting). It is suitable for various age groups, including children, adolescents, adults, and the elderly, and comes in multiple forms such as tablets, liquid solutions, sprays, patches, and extended-release formulations. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The nocturnal enuresis medication market research report is one of a series of new reports that provides nocturnal enuresis medication market statistics, including nocturnal enuresis medication industry global market size, regional shares, competitors with a nocturnal enuresis medication market share, detailed nocturnal enuresis medication market segments, market trends and opportunities, and any further data you may need to thrive in the nocturnal enuresis medication industry. This nocturnal enuresis medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nocturnal enuresis medication market consists of sales of fixed-dose combination drugs, nutraceuticals, and herbal supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.